100 Recruiting Studies Using Olaparib

Active clinical trials that use this intervention, sourced directly from the NIH registry.

Browse by condition

Trials Using Olaparib

🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Locally Advanced Uterine Corpus Leiomyosarcoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

📍 Ironwood Cancer & Research Centers ( Site 0007) — Chandler, Arizona

Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Pembrolizumab Plus Olaparib in LA-HNSCC

📍 Indiana University Simon Comprehensive Cancer Center — Indianapolis, Indiana

Squamous Cell Carcinoma of Head and Neck

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California

Locally Advanced Pancreatic Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

📍 UC San Diego Moores Cancer Center — La Jolla, California

Recurrent Glioblastoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

📍 Research Site — Foothill Ranch, California

Advanced Ovarian Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

📍 The University of Arizona Cancer Center - North Campus ( Site 0011) — Tucson, Arizona

Advanced Solid Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

📍 Research Site — Newnan, Georgia

Ovarian

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

📍 M D Anderson Cancer Center — Houston, Texas

BRCA1 Mutation Carrier

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona

Stage III Uterine Corpus Leiomyosarcoma AJCC v8

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Recurrent Endometrial Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Fallopian Tube Clear Cell Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Malignant Solid Neoplasm

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

📍 Cedars-Sinai Medical Center — Los Angeles, California

Fallopian Tube Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Fallopian Tube Clear Cell Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

📍 Research Site — Tucson, Arizona

Endometrial Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer

📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

📍 The Ottawa Hospital Cancer Centre — Ottawa, Ontario

Gynaecological Cancers

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

📍 Research Site — Anchorage, Alabama

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

📍 City of Hope Comprehensive Cancer Center — Duarte, California

Clear Cell Renal Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Study of INCB123667 in Subjects With Advanced Solid Tumors

📍 City of Hope Medical Center — Duarte, California

Solid Tumors

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

📍 UC San Diego Moores Cancer Center — La Jolla, California

Castration-Resistant Prostate Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

📍 UT MD Anderson Cancer Center — Houston, Texas

Advanced Malignant Solid Neoplasm

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

📍 UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California

Fallopian Tube Endometrioid Tumor

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

📍 University of Michigan Hospital — Ann Arbor, Michigan

Prostate Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

📍 Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey

Metastatic Pancreatic Ductal Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations

📍 University of California San Diego - Moores Cancer Center — La Jolla, California

Prostate Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

📍 Research Site — Daphne, Alabama

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

📍 Research Site — Duarte, California

Non-Small Cell Lung Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

📍 University of California Los Angeles — Los Angeles, California

Prostate Cancer Metastatic Castration-Resistant

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

📍 Dana Farber Cancer Institute — Boston, Massachusetts

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Selumetinib and Olaparib in Solid Tumors

📍 University of Texas MD Anderson Cancer Center — Houston, Texas

Malignant Neoplasm of Breast

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

📍 Research Site — Birmingham, Alabama

Metastatic Triple Negative Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

📍 University of Alabama at Birmingham — Birmingham, Alabama

Platinum Sensitive

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

📍 Tom Baker Cancer Centre — Calgary, Alberta

Ovarian Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial

📍 M D Anderson Cancer Center — Houston, Texas

Extensive Stage Lung Small Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

📍 UC San Diego Moores Cancer Center — La Jolla, California

Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska

Breast Inflammatory Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

📍 Clearview Cancer Institute — Huntsville, Alabama

Newly Diagnosed

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida

Small Cell Lung Cancer Extensive Stage

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

📍 Johns Hopkins Hospital — Baltimore, Maryland

Prostate

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

📍 UCSF Helen Diller Family CCC — San Francisco, California

Ovarian Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona

Anatomic Stage III Breast Cancer AJCC v8

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

📍 UC San Diego Health System - Encinitas — Encinitas, California

Advanced Bladder Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

A Dye for the Detection of Cancer of the Tongue and Mouth

📍 Memorial Sloan Kettering Basking Ridge (Consent Only) — Basking Ridge, New Jersey

Oral Squamous Cell Carcinoma (OSCC)

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

📍 Children's Hospital of Alabama — Birmingham, Alabama

Advanced Malignant Solid Neoplasm

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

📍 Dana-Farber Cancer Institute — Boston, Massachusetts

Recurrent Fallopian Tube Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

📍 Research Site — Stanford, California

Ovarian Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Endometrial Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

📍 Princess Margaret Cancer Centre — Toronto, Ontario

Glioma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

📍 Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland

Advanced Gastric Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

📍 Mayo Clinic in Arizona — Scottsdale, Arizona

Bile Duct Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Olaparib With Ceralasertib in Recurrent Osteosarcoma

📍 UCSF Benioff Children's Hospital; UCSF Pediatrics Hematology Oncology — San Francisco, California

Osteosarcoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

📍 Keck Medicine of USC Buena Park — Buena Park, California

Advanced Malignant Solid Neoplasm

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

📍 Research Site — Birmingham, Alabama

Metastatic Castration-resistant Prostate Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)

📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan

Prostate Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

📍 University of Alabama at Birmingham — Birmingham, Alabama

Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

📍 Moffitt Cancer Center — Tampa, Florida

Ovarian Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

📍 Research Site — Birmingham, Alabama

Urinary Bladder Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Colorectal Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska

Advanced Adrenal Gland Pheochromocytoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

📍 Research Site — Bonita Springs, Florida

Non-small Cell Lung Cancer NSCLC

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska

Metastatic Pancreatic Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma

📍 Washington University School of Medicine — St Louis, Missouri

Recurrent Head and Neck Squamous Cell Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

D9319C00001- 1L OC Mono Global RCT

📍 Research Site — Santiago,

Ovarian Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

📍 University of South Alabama, Mitchell Cancer Institute ( Site 0003) — Mobile, Alabama

Lung Neoplasms

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

📍 Houston Methodist Cancer Center — Houston, Texas

Breast Cancer Metastatic

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors

📍 Princess Margaret Cancer Centre — Toronto, Ontario

Mismatch Repair Proficient Colorectal Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

📍 UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California

Acute Myeloid Leukemia

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

📍 Research Site — Boca Raton, Florida

Ovarian Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Early Phase1 💊 Investigational Drug / Biologic

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

📍 M D Anderson Cancer Center — Houston, Texas

BRCA-Mutated Ovarian Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

📍 Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland

Metastatic Pancreatic Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

📍 Research Site — Los Angeles, California

Muscle Invasive Bladder Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic

Combination of Olaparib and Navitoclax in Women with HGSC and TNBC

📍 Sunnybrook Research Institute/Odette Cancer Centre — Toronto, Ontario

High Grade Serous Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska

Fallopian Tube Mucinous Adenocarcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

📍 Moffitt Cancer Center — Tampa, Florida

Uveal Melanoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

📍 UC San Diego Moores Cancer Center — La Jolla, California

Advanced Malignant Solid Neoplasm

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona

Fallopian Tube Carcinoma

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Olaparib In Metastatic Breast Cancer

📍 University of Alabama at Birmingham — Birmingham, Alabama

Metastatic Breast Cancer

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

📍 UC Irvine Health Cancer Center-Newport — Costa Mesa, California

Advanced Malignant Solid Neoplasm

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic

Study of LP-184 in Patients With Advanced Solid Tumors

📍 Highlands Oncology Group — Springdale, Arkansas

Advanced Solid Tumor

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Surgical Pembro +/- Olaparib w TMZ for rGBM

📍 Massachusetts General Hospital — Boston, Massachusetts

Glioblastoma

View Study & Checklist ➔

🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

📍 Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta

Breast Cancer Triple Negative

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

📍 Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland

Renal Cell Carcinoma

View Study & Checklist ➔

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

📍 Banner MD Anderson Cancer Center ( Site 0066) — Gilbert, Arizona

Breast Neoplasms

View Study & Checklist ➔

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Fallopian Tube Endometrioid Adenocarcinoma

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

Advanced Malignant Solid Neoplasm

View Study & Checklist ➔

RECRUITING Phase1 / Phase2 💊 Investigational Drug / Biologic

Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

📍 National Institutes of Health Clinical Center — Bethesda, Maryland

Gastroenteropancreatico Tumors

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Olaparib in Patients With HRD Malignant Mesothelioma

📍 University of Chicago Medical Center — Chicago, Illinois

Mesothelioma

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

📍 University of California, San Francisco — San Francisco, California

BRCA1 Mutation

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss

📍 The University of Texas M. D. Anderson Cancer Center — Houston, Texas

Advanced Cancer

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

📍 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland

Triple Negative Breast Cancer

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

📍 Cross Cancer Institute — Edmonton, Alberta

Lymphoma, Non-Hodgkin

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

📍 O'Neal Comprehensive Cancer Center at UAB — Birmingham, Alabama

Ovarian Cancer

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

📍 Investigative Site #108 — Goodyear, Arizona

Advanced Solid Tumor

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

📍 VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California

Metastatic Castrate Resistant Prostate Cancer

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska

Pancreatic Acinar Cell Carcinoma

View Study & Checklist ➔

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

📍 Holy Name Medical Center /ID# 279017 — Teaneck, New Jersey

Gynecologic Cancers

View Study & Checklist ➔

🟢 Recruiting Early Phase1 💊 Investigational Drug / Biologic

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

📍 OHSU Knight Cancer Institute — Portland, Oregon

Locally Advanced Pancreatic Ductal Adenocarcinoma

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

📍 START Midwest — Grand Rapids, Michigan

Triple Negative Breast Cancer (TNBC)

View Study & Checklist ➔